Genomics Biotech

How AI is reshaping drug discovery and programmable therapeutics, why investors poured billions, and what scientific and data bottlenecks remain.

Sino Biological’s XpressMax cell-free kit accelerates AI-driven antibody screening by enabling rapid protein synthesis, high-throughput assays and tighter experimental loops.

Tolemy Bio raised €1.4M led by Norrsken Evolve to launch Orbit, an AI-native platform that turns lab experiments into reusable intelligence for mid-sized biopharma.

Authoritative overview of how AI is transforming biotechnology: drug discovery, precision diagnostics, bioprocess optimization, clinical trials and market outlook.

Discover how MOLEA uses AI to design K9 LNPs for selective mRNA delivery to chondrocytes, cutting liver uptake 13.5-fold and protecting cartilage via Mmp13 editing.

How AI is reshaping biotech: protein folding, drug discovery, personalized medicine, and next steps for validation, data standards, and regulation.

How AI accelerates biotech commercialization: practical strategies for R&D, clinical validation, and market entry in China and the silver economy with ethical data partnerships.

AI has set the stage for biotech and longevity. Learn how AI accelerates drug discovery, market size estimates, economic benefits and investor risks.

Scala Biodesign raised $16M to scale its AI platform for protein engineering. Learn how its technology could shorten drug development timelines and aid partners like Boehringer Ingelheim.